A Phase I/II, randomized study evaluating the PK/PD of IM administration of ibalizumab patients with HIV-1 infection.

Trial Profile

A Phase I/II, randomized study evaluating the PK/PD of IM administration of ibalizumab patients with HIV-1 infection.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Ibalizumab (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 24 Jul 2017 According to a Theratechnologies media release, results from this study are presented at the 9th IAS Conference on HIV Science 2017.
    • 24 Jul 2017 Results published in the Theratechnologies media release.
    • 17 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top